Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367873 · ClinicalTrials.gov registry record · Phase 1
Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects
A Phase 1 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT01367873 is a Phase 1 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT01367873, a Phase 1 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-blind, placebo-controlled, ascending single-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matching placebo.
Interventions
- DRUG Placebo
- DRUG VIA-3196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367873
The ClinicalTrials.gov registry entry for NCT01367873 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01367873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01367873 about?
NCT01367873 is a clinical study titled "Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects". This is a single-center, randomized, double-blind, placebo-controlled, ascending single-dose study of VIA-3196 to evaluate the Safety, Pharmacokinetics and Pharmacodynamics of VIA-3196 in Healthy Subjects. Study dosing is organized into cohorts corresponding to escalating doses of VIA-3196 or matchi...
What is the current status of trial NCT01367873?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2011-06. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01367873?
The interventions under investigation include: Placebo (DRUG), VIA-3196 (DRUG).
Who is sponsoring clinical trial NCT01367873?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.